Loading...
In this industry-sponsored, phase 3, multinational, randomized, double-blinded, placebo-controlled trial, researchers assessed whether brexpiprazole — an atypical antipsychotic — was efficacious, safe, and well-tolerated in patients with Alzheimer disease (AD) dementia who had aggressive behaviors after an evaluation of reversible factors and a trial of non-pharmacological interventions. The diagnosis of AD dementia was based on validated clinical criteria. Patients were randomized in a 2:1 ratio to receive oral brexpiprazole or placebo for 12 weeks. Patients in the brexpiprazole group were further randomized in a 1:2 ratio to receive fixed doses of 2 mg per day or 3 mg per day. The primary endpoint was a change in scores on an agitation in…